SAMARTH LIFE SCIENCES PVT LTD

For FY 20-21, Mumbai-based Samarth Life Sciences recorded a revenue generation of Rs 44 crore in the biopharma space, maintaining a steady flow in business when compared to the revenue generated during FY 19-20 at Rs 43 crore. Since its inception in 1963, the company has built a product portfolio focused on therapeutics areas such as cardiology, oncology, neurology, pulmonology, antenatal medicines, IVF medicines, to name a few. The company researches, develops, manufactures and markets a broad range of life saving critical drugs.